Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders
MONROVIA, Calif. , March 6, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Bruce L.A. Carter , Ph.D., will not stand for reelection to the
View HTML
Toggle Summary Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
Abstracts available on the AACR Annual Meeting website
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2016 Financial Results
-- Reported promising preliminary data from Phase 2 study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) ----Announced strategic collaboration with Novartis for bispecific antibodies---- Robust cash position supports operations beyond 2020 ---- Management to host conference call today at 4:30 p.m. ET --
View HTML
Toggle Summary Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017
MONROVIA, Calif. , Feb. 22, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and
View HTML
Toggle Summary IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis
MONROVIA, Calif. , Feb. 18, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H.
View HTML
Toggle Summary Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference
MONROVIA, Calif. , Feb. 9, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
View HTML
Toggle Summary Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
MONROVIA, Calif. , Dec. 6, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced the completion of an underwritten public offering of 5,272,750 shares of its common stock, including 687,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to
View HTML
Toggle Summary Xencor, Inc. Prices Public Offering of Common Stock
MONROVIA, Calif. , Dec. 1, 2016 /PRNewswire/ --  Xencor, Inc. ( NASDAQ : XNCR) today announced the pricing of an underwritten public offering of 4,585,000 shares of its common stock, offered at a price to the public of $24.00 per share. The gross proceeds from this offering to Xencor are expected
View HTML
Toggle Summary Xencor, Inc. Announces Proposed Public Offering of Common Stock
MONROVIA, Calif. , Nov. 30, 2016 /PRNewswire/ --  Xencor, Inc. ( NASDAQ : XNCR) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to
View HTML
Toggle Summary Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting
- 9 of 11 patients (82%) achieved an initial response to therapy within 2 weeks of first dose --- 5 patients have attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -- Xencor management to host conference call today at 6:00 p.m. EST -
View HTML
Xencor © Copyright 2018